Back to top
more

Accelerate Diagnostics, Inc. (AXDX)

(Delayed Data from NSDQ)

$19.37 USD

19.37
270,467

+0.32 (1.68%)

Updated Jul 15, 2019 03:58 PM ET

Add to portfolio

3-Hold     3    

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1
2
3
4
5
S&P
Strong Buy
Buy
Hold
Sell
Strong Sell
500
24.91%
17.98%
9.64%
5.22%
2.12%
10.58%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

F Value | F Growth | A Momentum | F VGM

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

View All Zacks #1 Ranked Stocks

Trades from $1

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Zacks News

Zacks Equity Research

Accelerate Diagnostics (AXDX) Reports Q1 Loss, Misses Revenue Estimates

Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of 6.98% and -17.57%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

AXDX

Zacks Equity Research

Analysts Estimate Accelerate Diagnostics (AXDX) to Report a Decline in Earnings: What to Look Out for

Accelerate Diagnostics (AXDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AXDX

Zacks Equity Research

Earnings Preview: Accelerate Diagnostics (AXDX) Q4 Earnings Expected to Decline

Accelerate Diagnostics (AXDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AXDX

Zacks Equity Research

Accelerate Diagnostics (AXDX) Reports Q3 Loss, Lags Revenue Estimates

Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of 6.82% and -53.05%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

AXDX

Zacks Equity Research

Earnings Preview: Accelerate Diagnostics (AXDX) Q3 Earnings Expected to Decline

Accelerate Diagnostics (AXDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AXDX

Zacks Equity Research

Accelerate Diagnostics (AXDX) Surges: Stock Moves 6% Higher

Accelerate Diagnostics (AXDX) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

PEN AXDX

Zacks Equity Research

Accelerate Diagnostics (AXDX) Reports Q2 Loss, Misses Revenue Estimates

Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of -16.22% and -22.03%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

AXDX

Zacks Equity Research

Moving Average Crossover Alert: Accelerate Diagnostics, Inc. (AXDX)

Moving Average Crossover Alert: Accelerate Diagnostics, Inc. (AXDX)

AXDX

Zacks Equity Research

Accelerate Diagnostics (AXDX) in Focus: Stock Moves 6.7% Higher

Accelerate Diagnostics (AXDX) was a big mover last session, as the company saw its shares rise nearly 7% on the day.

IDXX AXDX

Zacks Equity Research

Accelerate Diagnostics (AXDX) In Focus: Stock Rises 5.1%

Accelerate Diagnostics (AXDX) was a big mover last session, as the company saw its shares rise more than 5% on the day.

AXDX EW

Zacks Equity Research

Here's Why You Can Buy Quest Diagnostics Stock Right Now

Quest Diagnostics Incorporated (DGX) is on a healthy growth trajectory of late.

INGN AXDX DGX ALGN

Zacks Equity Research

Illumina Offers FDA-Approved NGS Cancer Companion Test Kit

Illumina, Inc. (ILMN) recently announced that its FDA-approved next-generation sequencing (NGS) -- Extended RAS Panel has met the Current Colorectal Cancer Guidelines.

INGN AXDX ILMN ALGN

Zacks Equity Research

Lantheus Holdings at 52-Week High: What's Driving the Stock?

Share price of Lantheus Holdings, Inc. (LNTH), based in North Billerica, U.S., scaled a new 52-week high of $17.85 on Jun 30, eventually closing a bit lower at $17.65.

INGN AXDX LNTH ALGN

Zacks Equity Research

Envision Healthcare (EVHC) Acquires Anesthesia Associates

Envision Healthcare Corporation (EVHC), recently announced that it has acquired Connecticut based anesthesia physician group practice, Anesthesia Associates of New London, P.C.

INGN AXDX EVHC ALGN

Zacks Equity Research

Boston Scientific Rides on New Growth Plans amid Headwinds

On Jun 29 2017, we issued an updated research report on leading medical devices company, Boston Scientific Corporation (BSX).

INGN AXDX BSX ALGN

Zacks Equity Research

Abaxis (ABAX) Product Portfolio Strong, Competition Rife

On Jun 28, we issued an updated research report on California-based Abaxis, Inc. (ABAX).

INGN AXDX ABAX ALGN

Zacks Equity Research

BioScrip (BIOS) Strong on Infusion, Reimbursement a Drag

On Jun 28, we issued an updated research report on Elmsford, NY-based BioScrip, Inc. (BIOS), a leading Infusion Service provider.

INGN AXDX ALGN BIOS

Zacks Equity Research

Walgreens (WBA) Tops Q3 Earnings, Scraps Rite-Aid Deal

Walgreens Boots Alliance, Inc. (WBA) reported adjusted earnings per share (EPS) of $1.33 in third-quarter fiscal 2017, up 12.7% year over year.

INGN AXDX ALGN

Zacks Equity Research

Medtronic (MDT) Partners with Aetna for Type 1 & 2 Diabetes (Revised)

Medtronic plc (MDT) inked a new outcomes-based collaboration with Aetna (AET) for type 1 and type 2 diabetes patients who are on doses of multiple daily insulin injections.

INGN AXDX MDT ALGN

Zacks Equity Research

Zimmer Biomet (ZBH) Launches X-Ray-Based X-PSI Knee System

Zimmer Biomet Holdings, Inc. (ZBH) recently launched a X-ray-based Patient Specific Instrument, X-PSI Knee System.

INGN AXDX ZBH ALGN

Zacks Equity Research

Walgreens Boots-LabCorp Tie Up for Patient Service Centers

Walgreens Boots Alliance, Inc. (WBA), a major pharmacy-led, health and wellbeing enterprise, recently announced collaboration with leading diagnostic service provider LabCorp (LH).

INGN AXDX ALGN

Zacks Equity Research

IDEXX Well-Poised on Strong Fundamentals, Global Growth

On 29, we issued an updated research report on IDEXX Laboratories, Inc. (IDXX).

IDXX INGN AXDX ALGN

Zacks Equity Research

Quest Diagnostics to Buy Outreach Lab Service in Cape Cod

Quest Diagnostics Inc. (DGX) recently teamed up with Cape Cod Healthcare (CCHC) to obtain its outreach laboratory service business.

INGN AXDX DGX ALGN

Zacks Equity Research

Hologic (HOLX) Product Pipeline Strong, Competition Rife

On Jun 27, we issued an updated research report on Hologic, Inc. (HOLX), headquartered in Bedford, MA.

HOLX INGN AXDX ALGN

Zacks Equity Research

NuVasive (NUVA) Grappling with Odds: Should You Dump Stock?

On Jun 28, we issued an updated research report on San Diego, CA-based NuVasive, Inc. (NUVA), a major player in the global spine market.

INGN AXDX NUVA ALGN